Section Arrow
Quote
GDTC.NASDAQ
- CytoMed Therapeutics Limited
Quotes are at least 15-min delayed:2025/07/21 16:38 EDT
After Hours
Last
 2.16
+0.1599 (+7.99%)
Bid
2.02
Ask
2.18
High 2.18 
Low 2.02 
Volume 3085 
Regular Hours
Last
 2.0001
-0.0231 (-1.14%)
Day High 
2.26 
Prev. Close
2.0232 
1-M High
2.35 
Volume 
64.29K 
Bid
2.02
Ask
2.18
Day Low
2 
Open
2.1 
1-M Low
1.96 
Market Cap 
23.35M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.15 
20-SMA 2.2 
50-SMA 2.2 
52-W High 4.0499 
52-W Low 1.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.22/--
Enterprise Value
23.77M
Balance Sheet
Book Value Per Share
0.61
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
69.50K
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TNFATNF Pharmaceuticals Inc.0.1294+0.0419+47.89%-- 
After Hours 0.1155 -0.0139 -10.74%
NCNANuCana plc0.051+0.0033+6.92%-- 
After Hours 0.0532 +0.0022 +4.31%
PMNProMIS Neurosciences1.12+0.6799+154.49%5PE
After Hours 1.1 -0.02 -1.79%
SABSSAB Biotherapeutics2.7+0.13+5.06%-- 
After Hours 2.6105 -0.0895 -3.31%
RXRXRecursion Pharmaceuticals6.4+0.56+9.59%-- 
After Hours 6.385 -0.015 -0.23%
Quotes are at least 15-min delayed：2025/07/21 16:38 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.